ELAB

PMGC (ELAB) is a $1.37M nano-cap whose auditors and management both flag substantial doubt about its ability to continue as a going concern. The 10-K states plainly the company 'is dependent on obtaining funding from operations and the sale of debt or equity to continue as a going concern,' with net working capital falling to $2.93M from $4.25M and an accumulated deficit ballooning to -$21.0M. The numbers corroborate the warning: FY2025 revenue fell -65.5% to just $590K while the net loss widened -24.0% to -$7.75M, producing an absurd -1313% net margin and a -98.9% ROE. Operating cash flow was -$5.93M against $5.40M of cash — under a year of runway — so the company survives only by tapping capital markets, and shares already grew +63.9% in a single year. This is the definition of unknowable, dilution-driven risk.

The business itself has no coherent, durable identity. Management sold the entire skincare operation (its historical revenue engine) in January 2025 and reinvented ELAB as a 'diversified holding company,' stapling together a CNC-machining shop (AGA/Indarg), a packaging firm (Pacific Sun), a biopharma sub developing an unapproved engineered-probiotic (EL-22), and an investment vehicle (PMGC Capital). R&D was a token $147K. The revenue drop reflects the divestiture, but the forward plan — 'increasing revenue by achieving successful returns on capital through PMGC Capital' — is a hope, not a franchise, and the MD&A concedes there is 'no assurance that we will be able to reduce our operating cash burn to a level that can be sustained by our operating revenue.'